IRONWOOD PHARMACEUTICALS INC - COMMON-STOCK (IRWD)

Historical Holders from Q1 2014 to Q2 2025

Symbol
IRWD on Nasdaq
CUSIP
46333X108
Type / Class
Equity / COMMON-STOCK
Shares outstanding
162M
All holders as of June 30, 2025
Q2 2025
Total 13F shares, excl. options
146M
Holdings value
$105M
% of all portfolios
0.001%
Grand Portfolio weight change
0%
Number of holders
151
Number of buys
77
Number of sells
-116
Average Value change %
0%
Average buys %
+0%
Average sells %
0%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of IRONWOOD PHARMACEUTICALS INC - COMMON-STOCK (IRWD)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
VANGUARD GROUP INC 10.01% +2.1% $15.1M $471K 16.2M +3.22% The Vanguard Group Jun 30, 2025
ARMISTICE CAPITAL, LLC 8.47% +42.5% $13.8M $4.27M 13.7M +44.7% Armistice Capital, LLC Mar 31, 2025
BlackRock, Inc. 7.1% $11.4M 11.3M BlackRock, Inc. Feb 28, 2025
BARCLAYS PLC 6.88% $7.99M 11.1M Barclays PLC Jun 30, 2025
RENAISSANCE TECHNOLOGIES LLC 5.37% $8.68M 8.6M Renaissance Technologies LLC May 15, 2024
STATE STREET CORP 2.2% -60% $3.53M -$4.88M 3.5M -58% STATE STREET CORPORATION Mar 31, 2025
Pacer Advisors, Inc. 1.12% -88.6% $1.81M -$10M 1.79M -84.7% Pacer US Small Cap Cash Cows ETF Mar 31, 2025

Institutional Holders of IRONWOOD PHARMACEUTICALS INC - COMMON-STOCK (IRWD)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q2 146M $105M -$20M $0.72 151
2025 Q1 156M $229M -$26M $1.47 200
2024 Q4 164M $727M +$3.48M $4.43 222
2024 Q3 163M $672M -$58.3M $4.12 217
2024 Q2 171M $1.12B -$4.92M $6.52 226
2024 Q1 171M $1.49B +$22.5M $8.71 267
2023 Q4 150K $1.72M +$397K $11.44 2
2023 Q3 161M $1.55B -$46.1M $9.63 246
2023 Q2 165M $1.75B -$10M $10.64 247
2023 Q1 165M $1.74B -$23.7M $10.52 250
2022 Q4 168M $2.08B -$9.07M $12.39 244
2022 Q3 167M $1.74B -$61.3M $10.36 228
2022 Q2 172M $1.98B +$100M $11.53 224
2022 Q1 166M $2.09B -$58.3M $12.58 201
2021 Q4 167M $1.95B -$77.8M $11.66 203
2021 Q3 177M $2.31B +$37.8M $13.06 218
2021 Q2 174M $2.25B +$49.7M $12.87 202
2021 Q1 167M $1.87B -$7.89M $11.18 200
2020 Q4 167M $1.9B -$2.01M $11.39 187
2020 Q3 174M $1.57B -$70.7M $9.00 176
2020 Q2 178M $1.83B -$179K $10.32 192
2020 Q1 179M $1.8B +$4.19M $10.09 185
2019 Q4 177M $2.35B +$49.3M $13.31 189
2019 Q3 170M $1.46B +$87.8M $8.59 153
2019 Q2 161M $1.76B +$85.9M $10.94 146
2019 Q1 154M $2.09B +$91.4M $13.53 147
2018 Q4 149M $1.55B -$72.1M $10.36 139
2018 Q3 144M $2.66B -$61.2M $18.46 146
2018 Q2 148M $2.83B -$40.5M $19.12 142
2018 Q1 152M $2.34B -$158K $15.43 141
2017 Q4 151M $2.27B -$51.7M $14.99 152
2017 Q3 156M $2.47B +$150M $15.77 142
2017 Q2 147M $2.77B +$162M $18.88 161
2017 Q1 144M $2.46B +$311M $17.06 155
2016 Q4 139M $2.13B +$3.04M $15.29 156
2016 Q3 138M $2.18B +$18.9M $15.88 149
2016 Q2 135M $1.77B -$48.3M $13.07 139
2016 Q1 141M $1.54B +$6.63M $10.94 130
2015 Q4 140M $1.62B -$12M $11.59 132
2015 Q3 141M $1.47B -$34.4M $10.42 126
2015 Q2 142M $1.71B +$115M $12.06 135
2015 Q1 134M $2.14B +$8.54M $16.00 142
2014 Q4 133M $2.04B +$25.8M $15.32 127
2014 Q3 131M $1.7B +$65.4M $12.96 135
2014 Q2 106M $1.63B -$77.7M $15.33 138
2014 Q1 132M $1.62B +$223M $12.32 136